Immuneering (IMRX) News Today → Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad) Free IMRX Stock Alerts $1.63 -0.09 (-5.23%) (As of 08:51 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineImmuneering (IMRX) Price Target Decreased by 11.43% to 13.55msn.com - April 17 at 2:44 PMImmuneering Co. (NASDAQ:IMRX) Short Interest Up 10.3% in Marchamericanbankingnews.com - April 16 at 6:04 AMImmuneering Co. (NASDAQ:IMRX) Sees Significant Growth in Short Interestmarketbeat.com - April 15 at 9:25 AMImmuneering (NASDAQ:IMRX) Stock Rating Reaffirmed by Needham & Company LLCamericanbankingnews.com - April 14 at 3:36 AMNeedham & Company LLC Reiterates Buy Rating for Immuneering (NASDAQ:IMRX)marketbeat.com - April 12 at 8:14 AMImmuneering advances pancreatic cancer treatment trialinvesting.com - April 11 at 11:06 PMImmuneering Corporation: IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Modelsfinanznachrichten.de - April 9 at 3:55 PMIMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Modelsglobenewswire.com - April 9 at 12:00 PMImmuneering Co. (NASDAQ:IMRX) Given Consensus Rating of "Moderate Buy" by Brokeragesmarketbeat.com - April 9 at 4:10 AMCormorant Asset Management, Lp Sells 400,000 Shares of Immuneering Co. (NASDAQ:IMRX) Stockinsidertrades.com - April 5 at 4:32 AMImmuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conferenceglobenewswire.com - April 3 at 4:05 PMMizuho Trims Immuneering (NASDAQ:IMRX) Target Price to $8.00marketbeat.com - April 2 at 8:22 AMBuy Rating Affirmed for Immuneering on Solid Trial Progress and Insider Confidencemarkets.businessinsider.com - March 29 at 11:29 AMImmuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutationsglobenewswire.com - March 27 at 8:00 AM3 Stocks Insiders Are Buying That Analysts Loveinsidertrades.com - March 26 at 12:55 PMImmuneering Co. (NASDAQ:IMRX) Insider Harold Eugene Brakewood Buys 3,900 Sharesinsidertrades.com - March 26 at 5:18 AMInsider Buying: Immuneering Co. (NASDAQ:IMRX) Director Acquires 25,000 Shares of Stockinsidertrades.com - March 26 at 4:44 AMImmuneering Co. (NASDAQ:IMRX) Insider Acquires $10,023.00 in Stockmarketbeat.com - March 25 at 11:32 AMInsider Buying: Immuneering Co. (NASDAQ:IMRX) Insider Acquires 3,818 Shares of Stockinsidertrades.com - March 22 at 11:12 AMImmuneering CEO acquires $55.3k in company stockinvesting.com - March 21 at 6:59 PMLeah R. Neufeld Buys 3,818 Shares of Immuneering Co. (NASDAQ:IMRX) Stockmarketbeat.com - March 21 at 10:32 AMImmuneering Director Acquires 7.5% More Stockfinance.yahoo.com - March 21 at 8:17 AMImmuneering Co. (NASDAQ:IMRX) CEO Purchases $55,400.00 in Stockinsidertrades.com - March 20 at 7:19 AMInsider Buying: Immuneering Co. (NASDAQ:IMRX) CEO Acquires 20,000 Shares of Stockmarketbeat.com - March 19 at 8:14 PMCormorant Asset Management, Lp Sells 509,091 Shares of Immuneering Co. (NASDAQ:IMRX) Stockinsidertrades.com - March 19 at 4:28 AMImmuneering stock rebounds 34% following last week's selloffmsn.com - March 18 at 8:25 PMInsider Selling: Immuneering Co. (NASDAQ:IMRX) Major Shareholder Sells 509,091 Shares of Stockmarketbeat.com - March 18 at 7:55 PMImmuneering (NASDAQ:IMRX) Price Target Cut to $16.00marketbeat.com - March 18 at 6:44 PMImmuneering's (IMRX) "Neutral" Rating Reiterated at Guggenheimmarketbeat.com - March 18 at 5:10 PMWhy Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Sessionbenzinga.com - March 18 at 3:25 PMCanopy Growth, Outlook Therapeutics, Immuneering among healthcare moversmsn.com - March 18 at 10:24 AMU.S. shares lower at close of trade; Dow Jones Industrial Average down 0.49%msn.com - March 15 at 9:25 PMImmuneering: Hold Rating Amidst Potential and Uncertainties in Drug Efficacymarkets.businessinsider.com - March 15 at 4:24 PMCancer Treatment Focused Immuneering Faces Analyst Downgrades, Who Cite Underwhelming Solid Tumor Trial Datamarkets.businessinsider.com - March 15 at 4:24 PMImmuneering Co. (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from Analystsmarketbeat.com - March 15 at 8:47 AMNeedham & Company LLC Cuts Immuneering (NASDAQ:IMRX) Price Target to $15.00marketbeat.com - March 15 at 8:17 AMImmuneering (NASDAQ:IMRX) Lowered to Market Perform at TD Cowenmarketbeat.com - March 15 at 7:57 AMWhy Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Sessionbenzinga.com - March 14 at 2:24 PMWhat's Going On With Cancer-Focused Immuneering Stock On Thursday?msn.com - March 14 at 2:24 PMmarketbeat.com - March 14 at 11:10 AMmarketbeat.com - March 14 at 9:41 AMImmuneering IMM-1-104 Trial In RAS-Mutant Solid Tumors Shows Positive Results; Stock Upmarkets.businessinsider.com - March 14 at 9:24 AMImmuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumorsglobenewswire.com - March 14 at 7:00 AMImmuneering Corporation: Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumorsfinanznachrichten.de - March 13 at 2:26 PMImmuneering Appoints Thomas J. Schall, Ph.D. to its Board of Directorsfinance.yahoo.com - March 12 at 12:02 PMImmuneering Appoints Thomas J. Schall, Ph.D.globenewswire.com - March 12 at 8:00 AMImmuneering’s IMM-1-104 Progress Garners Buy Rating Amid Favorable Phase 2 Dose Determination and Anticipated Phase 1 Datamarkets.businessinsider.com - March 11 at 5:59 PMImmuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumorsglobenewswire.com - March 11 at 8:00 AMAnalyst Maintains Buy Rating on Immuneering Amidst Promising Clinical Progress and Extended Cash Runwaymarkets.businessinsider.com - March 6 at 5:17 PMImmuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024globenewswire.com - March 5 at 5:00 PM Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (Ad)Big Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver. Learn More Now IMRX Media Mentions By Week IMRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMRX News Sentiment▼0.000.44▲Average Medical News Sentiment IMRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMRX Articles This Week▼12▲IMRX Articles Average Week Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: FIXX News SCYX News RPHM News VAXX News GANX News KZR News GMTX News JAGX News DARE News APLM News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMRX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingElon Musk’s Controversial New Project: “Apollo”InvestorPlaceBiden out June 13; Kamala won’t replace him?Paradigm PressNew Trump BombshellThe Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
